The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice (Q84568101)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

ChEBI release 2020-05-28

S Vollert

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

N Kaessner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Heuser

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

G Hanauer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Dieckmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

D Knaack

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

H P Kley

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R Beume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

C Weiss-Haljiti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

1 reference

13 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

2779-2788

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22790061%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-012-2632-z

7 February 2020

exact match

0 references

cites work

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model

1 reference

12 December 2020

Emerging GLP-1 receptor agonists

1 reference

12 December 2020

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

1 reference

12 December 2020

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

1 reference

12 December 2020

Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.

1 reference

12 December 2020

Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells

1 reference

12 December 2020

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

1 reference

12 December 2020

RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes

1 reference

12 December 2020

The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

12 December 2020

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

1 reference

12 December 2020

Therapy in the early stage: incretins

1 reference

12 December 2020

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

12 December 2020

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

1 reference

12 December 2020

Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor

1 reference

12 December 2020

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

1 reference

12 December 2020

Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets

1 reference

12 December 2020

Diabetes, a New Mutation in the Mouse

1 reference

12 December 2020

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

12 December 2020

Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B.

1 reference

12 December 2020

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

1 reference

12 December 2020

Segmentation of the Pathophysiological Stages of Diabetic Changes in the db/db Mouse.

1 reference

12 December 2020

Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis

1 reference

12 December 2020

Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

1 reference

12 December 2020

The biology of incretin hormones

1 reference

12 December 2020

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

1 reference

12 December 2020

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

12 December 2020

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells

1 reference

12 December 2020

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

1 reference

12 December 2020

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

1 reference

12 December 2020